Coronavirus tally: Moderna flu vaccine trial falls short on one goal, sending stock down

Moderna Inc. MRNA, stock was down 6.6% premarket Friday, after the COVID vaccine maker said a trial of a flu vaccine candidate failed to meet one of its goals. "While we did not achieve non-inferiority for the Influenza B strains which are more frequent in younger populations, we have already…#modernaincmrna #stephenhoge
Source: Reuters: Health - Category: Consumer Health News Source Type: news